Page 33 - Recognizing axial spondyloarthritis - Janneke de Winter

REFERENCES
1. Said-Nahal R, Miceli-Richard C, Berthelot JM, Duché A, Dernis- Labous E, Blévec G Le, et al. The familial form of spondylarthropathy: A clinical study of 115 multiplex families. Arthritis Rheum 2000;43:1356–1365.
2. Said-Nahal R, Miceli-Richard C, D’Agostino MA, Dernis- Labous E, Berthelot JM, Duche A, et al. Phenotypic diversity is not determined by independent genetic factors in familial spondylarthropathy. Arthritis Rheum 2001;45:478–484.
3. Rahman P, Inman RD, Gladman DD, Reeve JP, Peddle L, Maksymowych WP. Association of interleukin-23 receptor variants with ankylosing spondylitis. Arthritis Rheum 2008;58:1020–5.
4. Burton PR, Clayton DG, Cardon LR, Craddock N, Deloukas P, Duncanson A, et al. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet 2007;39:1329– 37.
5. Anderson CA, Boucher G, Lees CW, Franke A, D’Amato M, Taylor KD, et al. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47. Nat Genet 2011;43:246–252.
6. Smolen JS, Schöls M, Braun J, Dougados M, Gerald OF, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017
update of recommendations by an international task force. Ann Rheum Dis 2018;77:3–17.
7. Gottlieb A, Menter A, Mendelsohn A, Shen Y-K, Li S, Guzzo C, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009;373:633– 40.
8. Poddubnyy D, Hermann KGA, Callhoff J, Listing J, Sieper J. Ustekinumab for the treatment of patients with active ankylosing spondylitis: Results of a 28-week, prospective, open-label, proof-of- concept study (TOPAS). Ann Rheum Dis 2014;73:817–823.
9. Baeten D, Østergaard M, Wei JC-C, Sieper J, Järvinen P, Tam L-S, et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo- controlled, proof-of-concept, dose- finding phase 2 study. Ann Rheum Dis 2018:1–8.
10. Kruithof E, Baeten D, Rycke L De, Vandooren B, Foell D, Roth J, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005;7:R569-80.
11. Vandooren B, Noordenbos T, Ambarus C, Krausz S, Cantaert T, Yeremenko N, et al. Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including
PERIPHERAL DISEASE IN AXIAL SPA
31
TWO